TICKERNERD
Menu
PBHPBHHealthcare · Drug Manufacturers - Specialty & Generic

PBH Stock Forecast: Prestige Consumer Healthcare, Inc. Price Predictions for 2026-2027

Last close, 14 Aug 2026
$51
+0.12% on the day

The 7 Wall Street analysts covering Prestige Consumer Healthcare, Inc. hold a median 12-month price target of $70 — +36.2% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 58 of 100 as at 13 Aug 2026 — in the upper half.

Market cap
$2.4B
Ticker Nerd rank
58 / 100
Median analyst target
$70
Analysts covering
7
Total return, dividends reinvested
1W
−6.3%
1M
+8.9%
YTD
−16.7%
1Y
−20.5%
From 52W high
−26.8%
From 52W low
+13.1%
$45
$70
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

PBH stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Prestige Consumer Healthcare, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 13 Aug 2026
58 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Volatility
96
Value
94
Quality
86
Revisions
67
Issuance
44
Growth
37
Size
34
Accruals
29
Momentum
21

Volatility (96): The share price has been relatively steady.

Momentum (21): The shares have been drifting down relative to others.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

PBH stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on PBH, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$40$50$60$70$80Oct 25Jan 26Apr 26Jul 26PBHHigh $75Median $70Low $55

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

What Wall Street says7 analysts
5 Buy2 Hold0 Sell
Low $55Median $70High $75

The green dot is the last close — the median target sits +36.2% from it.

Recent analyst actionsNewest first
DateFirmActionRatingTarget
15 May 2026Canaccord GenuityMaintainsBuy$86 → $72
14 May 2026OppenheimerDowngradePerform—
7 May 2026OppenheimerMaintainsOutperform—
2 Feb 2026JefferiesMaintainsHold—
7 Nov 2025Canaccord GenuityMaintainsBuy—
27 Oct 2025JefferiesMaintainsHold—
21 Oct 2025OppenheimerMaintainsOutperform—
8 Aug 2025Canaccord GenuityMaintainsBuy—
21 Mar 2025RBC CapitalMaintainsSector Perform—
13 Feb 2025OppenheimerMaintainsOutperform—
7 Feb 2025Canaccord GenuityMaintainsBuy—
7 Feb 2025DA DavidsonMaintainsBuy—
11 Nov 2024DA DavidsonMaintainsBuy—
24 Sept 2024JefferiesAssumesHold$70 → $76
28 Aug 2024DA DavidsonMaintainsBuy—
9 Aug 2024Canaccord GenuityMaintainsBuy—
9 Aug 2024DA DavidsonMaintainsBuy—
21 June 2024DA DavidsonUpgradeBuy—
21 May 2024Canaccord GenuityMaintainsBuy—
16 May 2024DA DavidsonMaintainsNeutral—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. PBH appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Estimates

PBH analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
EPS revision, 90 days
−4.4%
Analysts raising
0
Analysts cutting
7
Fundamentals

Prestige Consumer Healthcare, Inc. (PBH) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
14.4×

Cheaper than 48% of US stocks

Price / sales
2.2×

Cheaper than 50% of US stocks

Price / book
1.3×

Cheaper than 65% of US stocks

EV / EBITDA
13.6×

Cheaper than 28% of US stocks

Growth & margins
Revenue growth (YoY)
6.5%

Higher than 43% of US stocks

Earnings growth (YoY)
−38.5%

Higher than 13% of US stocks

Gross margin
51.3%

Higher than 64% of US stocks

Operating margin
20.8%

Higher than 80% of US stocks

Net margin
15.6%

Higher than 78% of US stocks

Returns & dividend
Return on equity
9.1%

Higher than 61% of US stocks

Return on assets
4.6%

Higher than 74% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Peers

PBH vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelDrug Manufacturers - Specialty & Generic
CompanyMarket capTKN rank
PBHPrestige Consumer Healthcare, Inc.$2.4B
58
BCRXBioCryst Pharmaceuticals, Inc.$2.4B
86
AMLXAmylyx Pharmaceuticals, Inc.$2.4B
53
RGCRegencell Bioscience Holdings Ltd.$2.6B
4
BHCBausch Health Cos., Inc.$2.3B
96
SUPNSupernus Pharmaceuticals, Inc.$2.7B
84
TRLVTrulieve Cannabis Corp.$1.8B
83

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Prestige Consumer Healthcare, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest PBH news & analysis

Here's Why Prestige Consumer Healthcare (PBH) is a Strong Value Stock

Zacks Investment Research · 14 Aug 2026positive

Zacks Investment Research reports that Prestige Consumer Healthcare (PBH) is a strong value stock per its Style Scores, which are presented as a way to identify strong, market-beating stocks for an investment portfolio. The item highlights PBH's value characteristics without providing specific figures.

Why it matters — This item signals to PBH watchers that the company is being flagged by Zacks' Style Scores as a strong value stock, an external assessment of its investment profile.

PBH or SYK: Which Is the Better Value Stock Right Now?

Zacks Investment Research · 12 Aug 2026neutral

A Zacks Investment Research article compares Prestige Consumer Healthcare (PBH) and Stryker (SYK) as value stock opportunities in the Medical - Products sector.

Why it matters — The article frames PBH as being evaluated against a major competitor for value-investing appeal, which could influence how investors perceive PBH relative to peers.

Premium Brands Q2 Earnings Call Highlights

MarketBeat · 10 Aug 2026neutral

Premium Brands (TSE: PBH) reported that its revised 2026 outlook stems from timing shifts in U.S. customer programs and the exit of a low-margin Ontario facility, rather than a deterioration in its underlying operating assumptions. The company characterised the change as related to those specific factors.

Why it matters — PBH watchers would care because the company attributes its outlook revision to timing and facility-exit factors rather than fundamental weakness in its operations.

Prestige Consumer Healthcare Q1 Earnings Call Highlights

MarketBeat · 9 Aug 2026positive

Prestige Consumer Healthcare reported first-quarter fiscal 2027 revenue growth of 6.5%, supported by broad-based category strength, the initial contribution from its Breathe Right acquisition and retailer order timing. The company raised its reported full-year outlook to incorporate Breathe Right and LaCorium Health while maintaining its prior outlook for organic revenue growth.

Why it matters — PBH watchers would note the company's revenue growth and its raised full-year reported outlook, which incorporate the impact of recent acquisitions while keeping its organic growth expectations unchanged.

Prestige Consumer Healthcare Inc. (PBH) Q1 2027 Earnings Call Transcript

Seeking Alpha · 6 Aug 2026neutral

Seeking Alpha published a transcript of Prestige Consumer Healthcare Inc.'s Q1 2027 earnings call, covering the company's first-quarter fiscal 2027 results and management commentary.

Why it matters — The full transcript gives PBH watchers a complete record of management's discussion of the company's latest quarterly performance.

FAQ

Frequently asked questions about PBH stock

What is the PBH stock price forecast for 2026-2027?

The 7 Wall Street analysts covering Prestige Consumer Healthcare, Inc. have a median 12-month price target of $70, with estimates ranging from $55 to $75. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is PBH stock a buy right now?

Of the 7 analysts covering Prestige Consumer Healthcare, Inc., 5 rate it a Buy, 2 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Prestige Consumer Healthcare, Inc. 58 out of 100 across roughly 4,600 US stocks as at 13 Aug 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank PBH?

As at 13 Aug 2026, Prestige Consumer Healthcare, Inc. ranks 58 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Volatility (96 of 100).

Will PBH stock go up?

No one can know that. What the data says: the median 12-month target from 7 analysts implies +36.2% from the last close, and Ticker Nerd's factor model ranks Prestige Consumer Healthcare, Inc. 58 out of 100 as at 13 Aug 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the PBH stock forecast for 2030?

No analyst covering Prestige Consumer Healthcare, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for PBH are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $55 to $75 over the next 12 months.

How has PBH stock performed over the past year?

Prestige Consumer Healthcare, Inc. returned -20.5% over the 12 months to 14 Aug 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Prestige Consumer Healthcare, Inc. do?

Prestige Consumer Healthcare Inc. is a corporation involved in the production and distribution of over-the-counter healthcare and household cleaning products.

What is the latest news on PBH?

The most recent item we track (Zacks Investment Research, 14 Aug 2026): "Here's Why Prestige Consumer Healthcare (PBH) is a Strong Value Stock". Zacks Investment Research reports that Prestige Consumer Healthcare (PBH) is a strong value stock per its Style Scores, which are presented as a way to identify strong, market-beating stocks for an investment portfolio. The item highlights PBH's value characteristics without providing specific figures.

Company

About Prestige Consumer Healthcare, Inc.

Prestige Consumer Healthcare Inc. is a corporation involved in the production and distribution of over-the-counter healthcare and household cleaning products. This company primarily focuses on providing solutions for everyday health and wellness needs. It operates within the consumer staples sector, influencing industries such as healthcare, wellness, and personal care goods. Prestige Consumer Healthcare Inc. offers a range of well-known products that cater to personal health care, featuring brands that span various categories, including analgesics, cough and cold remedies, gastrointestinal aids, and oral care products. The company sells its products through multiple channels including drug stores, groceries, and e-commerce platforms, reaching a broad consumer base. Prestige Consumer Healthcare Inc.'s role in the market centers on addressing consumer demands for accessible and reliable healthcare products, reinforcing its significance as a key player in enhancing and maintaining health across diverse demographics.

CEO Mr. Ronald M. Lombardi C.P.A. · 890 employees · United States · https://www.prestigebrands.com